Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
ApexOnco Front Page
Recent articles
As tinkering with HLA matching continues, is nearly as good as Breyanzi good enough?
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Antibody-drug conjugates hitting this target abound.
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Survival in Skyscraper-01 deteriorated, and bore no relation to the Cityscape result.
A BNT327 and BNT325 combo shows promise in platinum-resistant ovarian cancer.
